European capital markets are banking on reforms to position themselves as an attractive opportunity amidst a biopharma sector resurgence in 2026.

During a panel discussion at the 2026 Jefferies Global Healthcare Conference in London, taking place 16–19 November, life sciences lawyers and investors highlighted the challenging investment climate for biotechs in European markets, but a few pointed to moves made by some countries to entice international investment.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Jacqueline Mercier, partner at Goodwin, cited a statistic that of the 67 European biotechs to complete initial public offerings (IPOs) in the last six years, 66 have done so via stock exchanges outside of Europe. Regarding what this says about the European market’s credibility, fellow Goodwin partner Andrew Harrow said, “people are voting with their feet”.

Ongoing efforts to turn the tide

Amidst this environment, Harrow noted that London (and the UK) as an example of a market currently undergoing a transition. Turning away from its traditional focus on areas like mining and finances, he said London exchanges are turning their attention to the pool of high-growth companies found in biotech.

“There is a renewed focus on listing reform,” Harrow said. He pointed to reforms introduced by the Financial Conduct Authority (FCA) in 2024 to remove financial history requirements for companies to list their stock in the UK. “These building blocks are being put in place for London to come back as a potential venue for biotech listings,” he said.

Another issue faced more broadly in Europe compared to the US is its fractured capital markets, according to Søren Møller, managing investment director of seed investment at Novo Holdings. Møller points to the Nordic Compass as an effort to counter this weakness; this alliance of Nordic companies, investors, and others seeks more aligned capital markets across the Nordics.

Nordic biotechs like Solna, Sweden-based OneCarbon and CuraCell have previously told Pharmaceutical Technology about the difficulty companies in the region have in securing investment, according to their respective CEOs Ana Slipicevic and Jonas Båtelson. Rasmus Malmborg, special advisor at the Norwegian state initiative Innovation Norway, would like to see more specialist investors fund Nordic biotech, and in turn encourage generalist investors to do the same.

Hopefully, this sort of alignment of capital markets will spread further across Europe, said Jesper Wilkhund, CBO of Cinclus Pharma, at Jefferies. However, he added that the US is nonetheless seen as the better option for European companies to land an IPO, so it’s up to European drug developers to slowly build the credibility needed to attract US investors to come to Europe.

While the European capital market environment leaves much to be desired, opportunities for biotechs to raise funds in private markets persist. In Q2 2026, British biotechs raised £2.11bn ($2.84bn) in equity financing of which £2.05bn was from venture capital (VC) sources, as per a BioIndustry Association Report.

Against this backdrop, Bionyra Pharma’s CEO Frédéric Marrache told Pharmaceutical Technology there is still significant investment to be found in Europe. The biotech raised France’s largest Series A round for the sector in June 2026 with €143 ($165m), backed in part by Paris, France-based investors Sofinnova and Jeito. Marrache added that France is home to a range of pharma and biotech companies, investors, and sovereign wealth funds—state-owned funds—ingredients for the success of Bionyra’s Series A, in his opinion.